BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19493342)

  • 1. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.
    McRonald FE; Morris MR; Gentle D; Winchester L; Baban D; Ragoussis J; Clarke NW; Brown MD; Kishida T; Yao M; Latif F; Maher ER
    Mol Cancer; 2009 Jun; 8():31. PubMed ID: 19493342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
    Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
    PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic changes in the origin and development of renal cell carcinoma (RCC).
    Glavac D; Ravnik-Glavac M; Ovcak Z; Masera A
    Pflugers Arch; 1996; 431(6 Suppl 2):R193-4. PubMed ID: 8739330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
    Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
    Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
    Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
    Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
    Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T
    J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type.
    Meyer AJ; Hernandez A; Florl AR; Enczmann J; Gerharz CD; Schulz WA; Wernet P; Ackermann R
    Int J Cancer; 2000 Sep; 87(5):650-3. PubMed ID: 10925357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker.
    de Martino M; Klatte T; Haitel A; Marberger M
    Cancer; 2012 Jan; 118(1):82-90. PubMed ID: 21713763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
    Oh RR; Park JY; Lee JH; Shin MS; Kim HS; Lee SK; Kim YS; Lee SH; Lee SN; Yang YM; Yoo NJ; Lee JY; Park WS
    APMIS; 2002 Mar; 110(3):229-38. PubMed ID: 12076276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Foster K; Prowse A; van den Berg A; Fleming S; Hulsbeek MM; Crossey PA; Richards FM; Cairns P; Affara NA; Ferguson-Smith MA
    Hum Mol Genet; 1994 Dec; 3(12):2169-73. PubMed ID: 7881415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
    Batavia AA; Schraml P; Moch H
    Histopathology; 2019 Jan; 74(1):60-67. PubMed ID: 30565303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.